Business
Agenus Announces ESMO Oral Presentation of Two Clinical Trials of Balstilimab Alone and in Combination with Zalifrelimab in Recurrent or Metastatic Cervical Cancer
Data from two Phase 2 trials of balstilimab +/- zalifrelimab in patients with refractory cervical cancer were accepted as part of a late-breaking abstract and
About this update from Agenus Inc.
[{"type":"text","content":"Data from two Phase 2 trials of balstilimab +/- zalifrelimab in patients with refractory cervical cancer were accepted as part of a late-breaking abstract and will be presented as an oral presentation on September 18, 2020 at ESMO\n\n\nLEXINGTON, Mass., Aug. 26, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that data from two Phase 2 trials of balstilimab alone and in combination with zalifrelimab will be presented in an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Conference on September 18, 2020. \nData will be presented by Dr. David O'Malley, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine and the Director of the Division of Gynecologic Oncology at the James Cancer Hospital of The Ohio State University Comprehensive Cancer Center. Agenus remains on track to initiate rolling BLA submission for balstilimab monotherapy this quarter. Agenus also plans to have a completed data packet supporting BLA submission of balstilimab in combination with zalifrelimab by the end of this year.\nAbstract title: Single-agent Anti-PD-1 Balstilimab or in Combination with Anti-CTLA-4 Zalifrelimab for Recurrent/Metastatic (R/M) Cervical Cancer (CC). Preliminary Results of Two Independent Ph2 Trials [LBA34]\nSession: Gynaecological cancers \nDate: September 18, 2020\nAbout AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be rout...